10:09 AM EST, 02/13/2025 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Thursday it has signed an additional clinical trial collaboration and supply agreement with Gilead Sciences ( GILD ) to assess the efficacy and safety of IDE397 plus Gilead's Trodelvy in methylthioadenosine phosphorylase-deletion, or MTAP-deletion, non-small cell lung cancer.

The drugmakers will include patients with lung cancer in an ongoing phase 1 trial evaluating the combination regimen in MTAP-deletion urothelial cancer, with clinical updates expected this year, IDEAYA Chief Medical Officer Darrin Beaupre said.

IDEAYA said it is currently enrolling patients in a monotherapy expansion in lung and urothelial cancer and is projecting to begin a combination trial of IDE397 and IDE892 in H2.

Shares of IDEAYA fell 4.1%, while Gilead rose 2.2% in recent trading.

Price: 21.06, Change: -0.89, Percent Change: -4.05